6-Chloro-3-nitro-2-[(phenylsulfonyl)methyl]imidazo[1,2- b ]pyridazine.

As part of our ongoing scaffold-hopping work on an antikinetoplastid 3-nitroimidazo[1,2-a]pyridine scaffold, we explored 3-nitroimidazo[1,2-b]pyridazine as a potential new antikinetoplastid series. Using conditions previously described by our lab, we obtained 6-chloro-3-nitro-2-[(phenylsulfonyl)methyl]imidazo[1,2-b]pyridazine with 54% yield. In vitro activity of this compound was evaluated against both the promastigote form of Leishmania donovani, the axenic amastigote form of Leishmania infantum and the trypomastigote blood stream form of Trypanosomabrucei brucei, and its influence on cell viability was assessed on the HepG2 cell line. However, despite good activity against the trypomastigote blood stream form of T. b. brucei (EC₅₀ = 0.38 µM), it showed poor solubility in both HepG2 (CC₅₀ > 7.8 µM) and L. infantum axenic amastigotes (EC₅₀ > 1.6 µM) culture media, associated with a loss of activity against the promastigote form of L. infantum (EC₅₀ > 15.6 µM). [ABSTRACT FROM AUTHOR]